zunsemetinib (ATI-450)

P1, N=51, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting

P1/2, N=152, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting

P1, N=51, Not yet recruiting, Washington University School of Medicine | Trial completion date: Dec 2029 --> Mar 2030 | Initiation date: Dec 2024 --> Mar 2025

Here, we carried out a series of optimizations on CDD-450, aiming to enhance inhibition of the p38α-MK2 complex and improve pharmacokinetic properties...Evaluation in the Lewis rat adjuvant-induced arthritis model showed that compound 36 had a robust inflammation inhibitory effect and joint repair ability. Currently, compound 36 is being considered for preclinical development as a potential treatment for inflammatory diseases.

P1, N=51, Not yet recruiting, Washington University School of Medicine

P1/2, N=138, Not yet recruiting, Washington University School of Medicine

P2, N=47, Terminated, Aclaris Therapeutics, Inc. | Phase classification: P2a --> P2 | N=70 --> 47 | Trial completion date: Apr 2024 --> Dec 2023 | Recruiting --> Terminated | Trial primary completion date: Apr 2024 --> Dec 2023; Sponsor decision

P2, N=95, Completed, Aclaris Therapeutics, Inc. | Phase classification: P2a --> P2

P2, N=251, Completed, Aclaris Therapeutics, Inc. | Active, not recruiting --> Completed

HNSCC tumor MK2 inhibition enhances RT-mediated micronuclei formation and subsequent cGAS-STING-IFNβ1 levels. Loss of HNSCC MK2 leads to increased CD4-CD8 T-cell infiltration into the tumor and this effect is enhanced following RT. Targeting tumor MK2 may facilitate improved tumor control.